Press Release

Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows …

[Read more...] about Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development …

[Read more...] about Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 TAMPA, FL and LONDON – April 6, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an …

[Read more...] about Akari Therapeutics Announces Strategic Partnershipwith WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

TAMPA, FL and LONDON – March 18, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) …

[Read more...] about Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

TAMPA, FL and LONDON – March 17, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) …

[Read more...] about Akari Therapeutics Announces ADS Ratio Change